HCQ and Ivermectin included in multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19

Source: AAPS Author: Peter McCullough

video

From the Association of American Physicians and Surgeons:

It is our honor to bring Dr. McCullough back to “Doctors Are In” to discuss the latest on reducing COVID-19 hospitalization and death with early treatment with an in depth overview and update on ambulatory treatment studies and the new sequenced, multi-drug therapeutic regimen for high-risk COVID-19 patients.

It was also an honor to hear from Senator Bob Hall about his efforts to protect patient access to early treatment options.

See the report in ‘Reviews in Cardiovascular Medicine’ here:
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

Related: COVID-19: A realistic approach to community management – HCQ & IVM in concert with vaccination

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study

The results of a meta-analysis of 187 studies treating COVID-19 successfully with hydroxychloroquine are statistically irrefutable.

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.

Ivermectin for Covid-19: Database of all Ivermectin COVID-19 studies – 35 trials and growing

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »